Gaplinc RNA Regulates Survival in Severe Inflammation
UC Santa Cruz researchers identify an RNA molecule that shapes how the body survives lethal bacterial toxin exposure.
Updated on Nov. 17, 2026 in Life Sciences

University of California, Santa Cruz researchers discovered Gaplinc, a long non-coding RNA in macrophages that regulates survival during severe inflammation. The findings, published in the Proceedings of the National Academy of Sciences, suggest a possible new strategy for treating sepsis.
Why it matters
Sepsis occurs when the immune system overreacts to infection and triggers runaway inflammation that damages healthy organs. The discovery identifies a molecular regulator of that response, offering a potential target for future therapies.
In mouse models, 100% of Gaplinc-deficient mice survived lethal bacterial toxin levels that were fatal to normal mice. The CDC reports sepsis kills at least 20 percent of adults and 10 percent of children who develop it, but human clinical applicability remains untested.
The players
University of California, Santa Cruz
A public research university in Santa Cruz, California, part of the University of California system.
Centers for Disease Control and Prevention
The U.S. federal agency responsible for public health surveillance and disease prevention, which publishes the national sepsis statistics cited in the study context.
The details
Gaplinc binds to the enzyme MCCC1 inside mitochondria, linking gene expression with metabolic processing in immune cells. Gaplinc-deficient mice showed increased lysophosphatidylcholines and reduced free fatty acids in circulating blood fats.
Timeline
November 17, 2026: Study published in the Proceedings of the National Academy of Sciences reporting the Gaplinc findings.
Health Landscape
Sepsis is present in one out of every three hospital deaths across the United States, according to the CDC. This Gaplinc finding adds a molecular-level target to a field where treatment options remain limited against a condition that kills at least 350,000 U.S. adults annually.
If lipid-nanoparticle RNA therapeutics prove effective, they could temporarily rebalance Gaplinc levels during acute infection to reprogram cellular metabolism. Any such treatment would still need to clear human clinical trials before reaching patients.
The takeaway
Sepsis remains one of the deadliest conditions in hospitals, so discoveries that reveal how the immune system controls its own overreaction are worth tracking. Readers should watch for follow-up studies testing whether Gaplinc-targeted approaches work beyond mouse models.
Further reading
Explore more research in Life Sciences to see how molecular discoveries like Gaplinc connect to broader biomedical work.
Source note: This article includes information reported by Technology Networks.






